Arrowhead Pharmaceuticals Home | Arrowhead Pharmaceuticals, Inc. Plozasiran (formerly ARO-APOC3) is designed to reduce the production of the protein Apolipoprotein-CIII (ApoC3) through the natural RNA interference (RNAi) mechanism ApoC3 is a protein that is produced in liver cells and inhibits the formation and clearance of various lipids and lipoproteins, including triglycerides
Arrowhead Pharmaceuticals (ARWR) Stock Price Overview REDEMPLO's U S launch exceeded expectations, with strong prescription growth and positive payer feedback Major pipeline milestones are expected in Q3 Q4 2026, and the company is well-funded after significant capital raises and a lucrative licensing deal with Madrigal
Arrowhead Pharmaceuticals Inc (ARWR) Stock Price News - Google Arrowhead's products in development act through RNA interference mechanisms of action The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin
ARWR Stock Price Quote | Morningstar See the latest Arrowhead Pharmaceuticals Inc stock price (ARWR:XNAS), related news, valuation, dividends and more to help you make your investing decisions